mitomycin has been researched along with Triple Negative Breast Neoplasms in 5 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Homologous recombination (HR) prevents genomic instability by repair and protection of replication." | 1.56 | Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer. ( Becker, S; Borgmann, K; Classen, S; Jasin, M; Mansour, WY; Meyer, F; Parplys, AC; Petersen, C; Riepen, B; Rothkamm, K; Ruebe, C; Timm, S; Wikman, H, 2020) |
| "Patients with brain metastases of triple negative breast cancer (TNBC) have a poor prognosis owing to the lack of targeted therapies, the aggressive nature of TNBC, and the presence of the blood-brain barrier (BBB) that blocks penetration of most drugs." | 1.51 | Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages. ( Cai, P; He, C; Henderson, JT; Lip, H; Rauth, AM; Wang, Z; Wu, XY; Zhang, T, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Varzandeh, M | 1 |
| Varshosaz, J | 1 |
| Labbaf, S | 1 |
| Esmaeil, N | 1 |
| Duan, Z | 1 |
| Andrews, NP | 1 |
| Chen, CZ | 1 |
| Fan, M | 1 |
| Wang, J | 1 |
| Shen, J | 1 |
| Li, JJ | 1 |
| Chen, HW | 1 |
| Meyer, F | 1 |
| Becker, S | 1 |
| Classen, S | 1 |
| Parplys, AC | 1 |
| Mansour, WY | 1 |
| Riepen, B | 1 |
| Timm, S | 1 |
| Ruebe, C | 1 |
| Jasin, M | 1 |
| Wikman, H | 1 |
| Petersen, C | 1 |
| Rothkamm, K | 1 |
| Borgmann, K | 1 |
| Zhang, T | 2 |
| Lip, H | 1 |
| He, C | 2 |
| Cai, P | 2 |
| Wang, Z | 1 |
| Henderson, JT | 1 |
| Rauth, AM | 2 |
| Wu, XY | 2 |
| Prasad, P | 1 |
| Shan, D | 1 |
5 other studies available for mitomycin and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Sodium-borohydride exfoliated bismuthene loaded with Mitomycin C for chemo-photo-radiotherapy of triple negative breast cancer.
Topics: Bismuth; Borohydrides; Doxorubicin; Humans; Hyperthermia, Induced; Mitomycin; Phototherapy; Sodium; | 2023 |
Targeting bromodomain protein ANCCA/ATAD2 enhances the efficacy of DNA‑damaging chemotherapy agents and radiation.
Topics: ATPases Associated with Diverse Cellular Activities; BRCA1 Protein; Carboplatin; Cell Line, Tumor; C | 2020 |
Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Cell Line, T | 2020 |
Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Dox | 2019 |
Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response R | 2017 |